Gate2Brain
Financiado
Gate2Brain. Medicines beyond barriers.
In 2019, 30 million people worldwide were diagnosed with some form of CNS disorder and most of them lack effective treatment. This is largely explained by the fact that most of developed therapeutic molecules do not contain the ap...
In 2019, 30 million people worldwide were diagnosed with some form of CNS disorder and most of them lack effective treatment. This is largely explained by the fact that most of developed therapeutic molecules do not contain the appropriate properties to cross the BBB. Consequently, CNS disorders are the first cause of disability, and the second of mortality worldwide. Gate2Brain is a technologic platform based on a set of small peptide-shuttles that have the capacity to cross the BBB and carry to the CNS therapeutic cargoes that cannot reach the brain unaided. G2B-002, our flagship product, is a new therapeutic approach to fight against untreatable pediatric brain tumors with intact BBB. G2B novel delivery technology provides a non-invasive, non-antigenic, stable, soluble, and receptor-specific way to transport drugs across the BBB to reach the CNS. Our technology has the potential to be applied in a wide number of therapeutic areas and in transport through various biological barriers.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2023-03-16
Fecha Fin: 2025-03-31
Fecha Fin: 2025-03-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-16
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
GATE2BRAIN SL
No se ha especificado una descripción o un objeto social para esta compañía.
